29/07/2026 AbbVie announced European Commission approval of RINVOQ® for non-segmental vitiligo AbbVie announced European Commission approval of RINVOQ® for severe alopecia areata Johnson & Johnson announced a strategic collaboration with Sail Biomedicines to develop in vivo CAR-T therapies for autoimmune diseases AbbVie announced European Commission approval of RINVOQ® for non-segmental vitiligo (Ref) AbbVie announced that the European Commission (EC) approved RINVOQ® (upadac

27/07/2026 Argenx to acquire Forte Biosciences and adding FB102 to its Immunology pipeline InnoCare's fadeucravacitinib met it primary endpoint in Phase 3 Psoriasis study Jacobio dosed the first patient in China in Phase 2a trial of JAB-8263 for Rheumatoid arthritis Bambusa Therapeutics reported preliminary Proof-of-concept data for BTT001 in Atopic Dermatitis Argenx to acquire Forte Biosciences and adding FB102 to its Immunology pipeline (Ref) Argenx announced that the compa